Bayer’s Sevabertinib (BAY 2927088) Receives FDA Priority Review for HER2-Mutant Non-Small Cell Lung Cancer FDA Bayer has announced that its investigational compound, sevabertinib (BAY 2927088), has been granted Priority Review status by the U.S. Food and Drug Administration (FDA) for…
Verastem Oncology Publishes Phase 2 RAMP 201 Results: Avutometinib + Defactinib in Recurrent LGSOC Verastem Oncology, focused on therapies for RAS/MAPK pathway-driven cancers, today announced the primary outcomes of the Phase 2 RAMP 201 trial have been published online in JCO.…
Merck Unveils Comprehensive Oncology Advances at ASCO 2025, Targeting Advanced Cancers and Rare Tumors Merck, a global leader in science and technology innovation, today announced the presentation of a broad spectrum of new clinical data across more than a dozen…
bioAffinity Technologies Detects Second Primary Lung Cancer Using CyPath® Lung bioAffinity Technologies, Inc. has recently released a compelling case study in which its CyPath® Lung test played a crucial role in detecting a second primary lung cancer in a high-risk…
U.S. and China Grant Breakthrough Therapy Designation to Bayer’s Sevabertinib as First-Line Therapy for HER2-Mutant Lung Cancer The U.S. Food and Drug Administration (FDA) and China’s Center for Drug Evaluation (CDE) have granted Breakthrough Therapy Designation to sevabertinib for first-line…
Summit Therapeutics Inc. announced that data from the Phase III HARMONi-6 trial will be highlighted during the prestigious Presidential Symposium at the upcoming European Society for Medical Oncology (ESMO) Congress 2025, taking place in Berlin, Germany, from October 17–21, 2025.…
Bayer and Vividion to Showcase Oncology Advances at AACR 2025 Bayer and Vividion Therapeutics, Inc. (Vividion), a wholly owned subsidiary of Bayer AG, are set to present groundbreaking research from their oncology pipelines at the American Association for Cancer Research…
Bayer has reported promising results from the Phase I/II SOHO-01 study, which is evaluating BAY 2927088 for advanced HER2-mutant non-small cell lung cancer (NSCLC). The data were presented at the IASLC 2024 World Conference on Lung Cancer (WCLC) in San…
Bayer is set to present new oncology data at the European Society for Medical Oncology (ESMO) Congress, taking place in Barcelona, Spain, from September 13-17, 2024. A major focus will be on prostate cancer, with late-breaking data on darolutamide and…